Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index.

• Authors: Massimo Breccia, Giuseppina Loglisci, Adriano Salaroli, Alessandra Serrao, Giuliana Alimena
• Journal: Leukemia research (Leuk Res) Vol. 36 Issue 4 Pg. e66-7 (Apr 2012) ISSN: 1873-5835 [Electronic] England
• PMID: 22218012 (Publication Type: Letter)

Chemical References

• Antineoplastic Agents
• Blood Glucose
• Pyrimidines
• nilotinib

Topics

• Adult
• Aged
• Antineoplastic Agents (adverse effects)
• Blood Glucose (drug effects)
• Body Mass Index
• Clinical Trials as Topic
• Diabetes Mellitus, Type 2
• Female
• Humans
• Hyperglycemia (chemically induced)
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)
• Male
• Middle Aged
• Pyrimidines (adverse effects)
• Young Adult